TG Therapeutics, Inc. (NASDAQ:TGTX) Receives $50.25 Average PT from Analysts

Shares of TG Therapeutics, Inc. (NASDAQ:TGTX) have been given an average recommendation of “Moderate Buy” by the five research firms that are presently covering the company, MarketBeat reports. Two equities research analysts have rated the stock with a hold rating, two have given a buy rating and one has given a strong buy rating to the company. The average twelve-month price objective among analysts that have covered the stock in the last year is $50.25.

Several equities analysts have commented on TGTX shares. B. Riley raised shares of TG Therapeutics to a “strong-buy” rating in a research report on Tuesday, November 4th. Wall Street Zen upgraded TG Therapeutics from a “hold” rating to a “buy” rating in a research note on Sunday, December 14th. HC Wainwright assumed coverage on TG Therapeutics in a research note on Monday, October 6th. They set a “buy” rating and a $60.00 target price for the company. Weiss Ratings reissued a “hold (c+)” rating on shares of TG Therapeutics in a research report on Monday, December 22nd. Finally, JPMorgan Chase & Co. raised their target price on shares of TG Therapeutics from $46.00 to $49.00 and gave the company an “overweight” rating in a report on Monday, November 3rd.

TG Therapeutics Trading Down 1.0%

Shares of NASDAQ TGTX opened at $30.77 on Friday. The company has a current ratio of 3.82, a quick ratio of 2.89 and a debt-to-equity ratio of 0.40. The stock has a market capitalization of $4.89 billion, a PE ratio of 11.07 and a beta of 2.01. TG Therapeutics has a twelve month low of $25.28 and a twelve month high of $46.48. The stock has a fifty day simple moving average of $32.08 and a 200-day simple moving average of $33.18.

TG Therapeutics (NASDAQ:TGTX) last announced its earnings results on Monday, November 3rd. The biopharmaceutical company reported $2.43 EPS for the quarter, beating analysts’ consensus estimates of $0.24 by $2.19. The company had revenue of $161.71 million during the quarter, compared to analysts’ expectations of $152.12 million. TG Therapeutics had a return on equity of 133.24% and a net margin of 84.13%.TG Therapeutics’s revenue for the quarter was up 92.7% on a year-over-year basis. During the same period last year, the business posted $0.02 EPS. On average, equities analysts forecast that TG Therapeutics will post 0.08 earnings per share for the current year.

Insider Activity

In related news, Director Yann Echelard sold 5,000 shares of the business’s stock in a transaction on Monday, November 24th. The shares were sold at an average price of $32.57, for a total transaction of $162,850.00. Following the completion of the transaction, the director owned 223,816 shares in the company, valued at approximately $7,289,687.12. The trade was a 2.19% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Company insiders own 10.64% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in TGTX. State Street Corp raised its position in TG Therapeutics by 2.5% in the 2nd quarter. State Street Corp now owns 7,618,238 shares of the biopharmaceutical company’s stock valued at $274,180,000 after purchasing an additional 184,339 shares during the last quarter. Geode Capital Management LLC boosted its position in TG Therapeutics by 6.3% during the second quarter. Geode Capital Management LLC now owns 3,490,457 shares of the biopharmaceutical company’s stock worth $126,033,000 after purchasing an additional 207,890 shares in the last quarter. Goldman Sachs Group Inc. raised its position in TG Therapeutics by 21.9% during the first quarter. Goldman Sachs Group Inc. now owns 1,919,416 shares of the biopharmaceutical company’s stock worth $75,683,000 after acquiring an additional 345,059 shares during the last quarter. Hood River Capital Management LLC increased its position in TG Therapeutics by 0.7% during the second quarter. Hood River Capital Management LLC now owns 1,567,506 shares of the biopharmaceutical company’s stock worth $56,415,000 after buying an additional 11,018 shares in the last quarter. Finally, Invesco Ltd. raised its stake in TG Therapeutics by 12.8% in the 3rd quarter. Invesco Ltd. now owns 1,094,334 shares of the biopharmaceutical company’s stock valued at $39,533,000 after purchasing an additional 124,429 shares during the last quarter. Hedge funds and other institutional investors own 58.58% of the company’s stock.

TG Therapeutics Company Profile

TG Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in New York City that specializes in developing targeted therapies for hematological malignancies and autoimmune diseases. The company’s research strategy focuses on the modulation of B-cell biology through novel antibody and small‐molecule agents. Since its founding in 2003, TG Therapeutics has built a diversified portfolio aimed at addressing unmet medical needs in oncology and immunology.

In December 2022, TG Therapeutics achieved its first commercial milestone when ublituximab-xiiy (marketed as Briumvi® in collaboration with Biogen) received U.S.